Support from the NEI continued for further follow-up of the CIGTS cohort through the end of 2004, and further support for follow-up was provided by an unrestricted grant from Allergan Inc (Irvine, California). This has led to a very rich long-term database with important information on how visual field and HR-QOL changes over time as well as a large number of secondary outcomes available up to 10 years after treatment initiation. Since the interim reports on clinical and HR-QOL outcomes, 2 reports from the CIGTS group have focused on visual field information. One article addressed factors associated with visual field severity at baseline,12 of which, the more striking (all P < .001) were black race, higher IOP, lower visual acuity, and a center effect. Variability in visual field measurement at baseline was found to be influenced by expected factors (eg, decreased patient alertness and increased age) and an unexpected factor (current smokers had increased variability). The transition to Swedish Interactive Thresholding Algorithm (SITA) from full-threshold visual field testing that occurred later on in CIGTS follow-up permitted us to evaluate similarities and differences in outcome measures from these 2 methods of measuring visual field.13 A more clinically oriented report addressed the occurrence of complications in the perioperative period after 465 trabeculectomies performed in the 300 patients randomized to the surgery arm.14 Intraoperative complications were found in 12% of patients, with anterior chamber bleeding as the most frequent (8%). In the first month after trabeculectomy, complications found in more than 10% of operated eyes included a shallow or flat anterior chamber (13%), encapsulated bleb (12%), ptosis (12%), serous choroidal detachment (11%), and anterior chamber bleeding or hyphema (10%). The investigators concluded that among the many complications reported, none were severe or expected to cause sequelae.